Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
Autore:
Bast, RC; Ravdin, P; Hayes, DF; Bates, S; Fritsche, H; Jessup, JM; Kemeny, N; Locker, GY; Mennel, RG; Somerfield, MR;
Indirizzi:
Amer Soc Clin Oncol, Hlth Serv Res, Alexandria, VA 22314 USA Amer Soc ClinOncol Alexandria VA USA 22314 Res, Alexandria, VA 22314 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 6, volume: 19, anno: 2001,
pagine: 1865 - 1878
SICI:
0732-183X(20010315)19:6<1865:2UORFT>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYMERASE-CHAIN-REACTION; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; HER-2/NEU GENE AMPLIFICATION; C-ERBB-2 ANTIGEN LEVELS; TOPOISOMERASE II-ALPHA; GROWTH-FACTOR RECEPTOR; IN-SITU HYBRIDIZATION; PROGNOSTIC-SIGNIFICANCE; DNA-PLOIDY; PROGESTERONE-RECEPTOR;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
117
Recensione:
Indirizzi per estratti:
Indirizzo: Bast, RC Amer Soc Clin Oncol, Hlth Serv Res, 1900 Duke St,Ste 200, Alexandria, VA 22314 USA Amer Soc Clin Oncol 1900 Duke St,Ste 200 Alexandria VA USA 22314
Citazione:
R.C. Bast et al., "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology", J CL ONCOL, 19(6), 2001, pp. 1865-1878

Abstract

Objective: To update the 1997 clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast and colorectal cancers. These guidelines are intended for use in the care of patients outside of clinical trials. Options: Six tumor markers for colorectal cancer and eight for breast cancer were considered. They could be recommended or not for routine use or forspecial circumstances. In addition to carcinoembryonic antigen (CEA) and CA 15-3, CA 27.29 was also considered among the serum tumor markers for breast cancer. Outcomes: In general, the significant health outcomes identified for use in making clinical practice guidelines (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used. Evidence: A computerized literature search from 1994 to March 1999 was performed. Values: The same values for use, utility, and levels of evidence were usedby the committee. Benefits, Harms, and Costs: The same benefit, harms, and costs were used. Recommendation: Changes were recommended (see Appendix). Validation: The updated recommendations were validated by external review by the American Society of Clinical Oncology's (ASCO's) Health Services Research Committee and by ASCO's Board of Directors. Sponsor: American Society of Clinical Oncology. (C) 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:44:06